Anagliptin Explained

Anagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan.^[1] It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".^[2]

Notes and References

1. Graul AI, Lupone B, Cruces E, Stringer M . 2012 in review - part I: the year's new drugs & biologics . Drugs of Today . 49 . 1 . 33–68 . January 2013 . 23362494 . 10.1358/dot.2013.49.1.1933991 . dead . https://web.archive.org/web/20131103135328/http://thomsonreuters.com/business-unit/science/pdf/ls/years_new_drugs_biologics-2012.pdf . 2013-11-03 .
2. Kato N, Oka M, Murase T, Yoshida M, Sakairi M, Yamashita S, Yasuda Y, Yoshikawa A, Hayashi Y, Makino M, Takeda M, Mirensha Y, Kakigami T . 6 . Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor . Bioorganic & Medicinal Chemistry . 19 . 23 . 7221–7 . December 2011 . 22019046 . 10.1016/j.bmc.2011.09.043 .